ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Bryant Furlow

Bryant Furlow

Posts by Author

Five years after treatment, low-dose postsurgical radioiodine (I-131) ablation for low-risk thyroid cancer offers outcomes equivalent to those seen following higher-dose ablation, according to a long-term follow-up analysis by French researchers.

A MALDI-TOF mass spectrometry (MassARRAY) mutation-detection panel shows promise for improving the presurgical diagnosis of thyroid cancers with fine needle aspirations, according to a pilot study.

High-risk ultrasound findings strongly indicate that thyroid nodules are malignant, even when nodules are cytologically indeterminate following find needle aspiration.

A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.

Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.

Adding carboplatin to cabazitaxel was safe and associated with improved PFS among men with aggressive variant castration-resistant prostate cancer.

Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.

Post-treatment CT surveillance does not offer better survival rates vs clinical symptoms evaluation for tumor recurrence in locally advanced non–small-cell lung cancer.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.